Challenges in the translation and commercialization of cell therapies

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Dodson, Brittany P ^a   Levine, Aaron D ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCE; CYTOLOGY; MOLECULES; PATIENT TREATMENT;

CELL THERAPY; CELL-BASED; QUALITATIVE INTERVIEWS; REGULATORY PROCESS; SCALING-UP; SMALL MOLECULES;

CELLS;

REMESTEMCEL L; SIPULEUCEL T;

ACUTE GRAFT VERSUS HOST DISEASE; ADDRESSING DISTRIBUTION LOGISTICS; ARTICLE; BONE ALLOGRAFT; BURN; CELL THERAPY; CHONDROCYTE IMPLANT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; COMMERCIAL PHENOMENA; COMMERCIALIZATION; CROHN DISEASE; DEVICE APPROVAL; DRUG APPROVAL; ENCOURAGING ADOPTION; FUNDING; GOVERNMENT REGULATION; HEALTH CARE COST; HISTORY OF MEDICINE; HUMAN; INTERVIEW; POSTMARKETING SURVEILLANCE; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUALITATIVE INTERVIEW; REIMBURSEMENT; RETROSPECTIVE STUDY; SCALE UP; SKIN ALLOGRAFT; SYSTEMATIC REVIEW; TISSUE SCAFFOLD; TRANSLATIONAL RESEARCH; WOUND DRESSING; WOUND HEALING; BIOLOGICAL THERAPY; TRENDS;

CELL- AND TISSUE-BASED THERAPY; HUMANS;

EID: 84938592470     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0190-4     Document Type: Article

References (76)

1. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med. 2011;6(3):265-72.
2. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
3. Fischbach MA, Bluestone JA, Lim WA. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med. 2013;5(179):179ps7.
4. Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000-2010). Regen Med. 2012;7(4):455-62.
5. Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014;9(1):27-39.
6. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med. 2010;16(5):203-9.
7. Brindley DA, Reeve BC, Sahlman WA, Bonfiglio GA, Davie NL, Culme-Seymour EJ, et al. The impact of market volatility on the cell therapy industry. Cell Stem Cell. 2011;9(5):397-401.
8. Rao MS. Funding translational work in cell-based therapy. Cell Stem Cell. 2011;9(1):7-10.
9. Heathman TR, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt CJ. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10(1):49-64.
10. Ahrlund-Richter L, De Luca M, Marshak DR, Munsie M, Veiga A, Rao M. Isolation and Production of Cells Suitable for Human Therapy: Challenges Ahead. Cell Stem Cell. 2009;4(1):20-6.
11. Preti RA. Bringing safe and effective cell therapies to the bedside. Nat Biotech. 2005;23(7):801-4.
12. Parson A. The long journey from stem cells to medical product. Cell. 2006;125(1):9-11.
13. Ledford H. Therapeutic cancer vaccine survives biotech bust. Nature. 2015;519(7541):17-8.
14. Pangarkar N, Pharoah M, Nigam A, Hutmacher DW, Champ S. Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine. Regen Med. 2010;5(5):823-35.
15. Epicel. http://www.epicel.com/ . Accessed February 27 2015.
16. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331-43.
17. Green H. The birth of therapy with cultured cells. Bioessays. 2008;30(9):897-903.
18. Powell A. Recalling a Lab-led Rescue. In: Harvard Gazette. 2013. http://news.harvard.edu/gazette/story/2013/09/with-lives-in-balance-a-lab-led-rescue/ . Accessed February 27 2015.
19. Oransky I. With 16 Doctors on Review. Harvard Crimson: Some Criticize Strict Policy; 1992.
20. De Bie C. Genzyme: 15 years of cell and gene therapy research. Regen Med. 2007;2(1):95-7.
21. Whalen J. Spencer M. Wall Street Journal: Sanofi Wins Long-Sought Biotech Deal; 2011.
22. Aastrom Nabs Sanofi's Cell Therapy Business for $6.5 M. In: Genetic Engineering & Biotechnology News. 2014. http://www.genengnews.com/gen-news-highlights/aastrom-nabs-sanofi-s-cell-therapy-business-for-6-5m/81249768/ . Accessed February 27 2015.
23. Carticel. http://www.carticel.com/ . Accessed February 27 2015.
24. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994;331(14):889-95.
25. Spear L. A Leading Edge in the Repair of Cartilage. New York Times. 1998 August 2.
26. Eaton ML. Ethics and the business of bioscience. Stanford, Calif.: Stanford Business Books; 2004.
27. Genzyme unit freed to by FDA to resume tissue repair service. Wall Street Journal. 1995 July 7; p. B3.
28. Food and Drug Administration. August 22, 1997 Approval Letter - Carticel. http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm171702.htm . Accessed March 6 2015.
29. Genzyme Corporation. Genzyme Announces Positive Results From Carticel(R) Study At Major Sports Medicine Meeting. Medical News Today. 2007. http://www.medicalnewstoday.com/releases/76976.php . Accessed February 27 2015.
30. Provenge (sipuleucel-T). http://www.provenge.com/ . Accessed February 27 2015.
31. Landau E. 'Landmark' cancer vaccine gets FDA approval. CNN.com. 2010. http://www.cnn.com/2010/HEALTH/04/27/provenge.prostate.cancer.fda/ . Accessed February 27 2015.
32. Timmerman L. Dendreon May Not Survive Its Success: Q&A with Founder Chris Henney, Part 1 Xconomy.com. 2009. http://www.xconomy.com/seattle/2009/07/27/dendreon-may-not-survive-its-success-qa-with-founder-chris-henney-part-1/ . Accessed February 27 2015.
33. The regulator disapproves. Nat Biotechnol. 2008;26(1):1.
34. Timmerman L. Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Xconomy.com. 2011. http://www.xconomy.com/national/2011/08/08/dendreon-wounds-are-self-inflicted-not-the-start-of-a-biotech-industry-virus/ . Accessed February 27 2015.
35. Silverman E. A Dendreon Post Mortem? Maybe Not Yet, But... Forbes.com. 2012. http://www.forbes.com/sites/edsilverman/2012/08/01/a-dendreon-post-mortem-maybe-not-yet-but/ . Accessed February 27 2015.
36. Grunbaum R. Biotech's pitfalls tripped up Dendreon, led it to bankruptcy Seattle Times. 2014 November 10.
37. Corrigan T. Valeant Approved to Buy Dendreon Assets for $495 Million. Wall Street Journal. 2015 February 20.
38. Apligraf. http://www.apligraf.com/ . Accessed February 27 2015.
39. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-8.
40. Organogenesis Company Profile. http://www.organogenesis.com/company/company-profile.html . Accessed February 27 2015.
41. Donnelly JM. Organogenesis' decade of regeneration. Boston Business Journal. 2012 October 12.
42. Connolly A. Novartis squares off over Organogenesis' Apligraf. Boston Business Journal. 2002 October 7.
43. Seiffert D. Local biotechs say proposed Medicare and Medicaid change will crimp innovation. Boston Business Journal. 2013 November 19.
44. Fikes BJ. Shire sells Dermagraft to Organogenesis. San Diego Union-Tribune. 2014 January 22.
45. Dermagraft. http://www.dermagraft.com/ . Accessed February 27 2015.
46. Asuda G. Firm Makes Strides in Growing Human Tissue. Los Angeles Times. 1990 March 22.
47. Advanced Tissue Sets Venture For Experimental Dermagraft. Wall Street Journal. 1996 April 30.
48. Bigelow BV. In Development of Bio-Engineered Skin Tissue, Third Try is Charm for Advanced BioHealing Xconomy. 2009. http://www.xconomy.com/san-diego/2009/12/23/in-development-of-bio-engineered-skin-tissue-third-try-is-charm-for-advanced-biohealing/ . Accessed 2015 Feburary 27.
49. Stovall S, Solsman JE. Shire to Buy Advanced BioHealing for $750 Million. Wall Street Journal. 2011 May 18.
50. Nuvasive - Osteocel Bone Graft. http://www.nuvasive.com/patient-solutions/nuvasive-integrated-surgical-solutions/osteocel-bone-graft/ . Accessed March 6 2015.
51. Bishop T. Stem cell use part of therapy: City biotech Osiris incorporates adult cells in bone graft. Baltimore Sun. 2005 September 23.
52. Osiris Therapeutics. Osiris Launches the Osteocel Product Line. September 22, 2005. http://investor.osiris.com/releasedetail.cfm?releaseid=202617 . Accessed March 6 2015.
53. Dimond PF. Osiris' Race to Market an FDA-Approved Stem Cell Product. Genetic Engineering & Biotechnology News. 2010 May 18.
54. Bishop T. Osiris stem cell line sale OK'd. Baltimore Sun. 2008 July 25.
55. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol. 2009;27(11):966-7.
56. Guidera M. From cells arises Osiris: Company was started four years ago in new area of medicine. Baltimore Sun. 1997 June 29.
57. Salganik MW. 2008 may be year of stem cell gains: Columbia's Osiris has high hopes for human trials in works. Baltimore Sun. 2007 December 28.
58. Busa Consulting LLC. Counting Coup: Is Osiris Losing Faith in Prochymal? August 5, 2013. http://busaconsultingllc.com/scsi/organelles/counting_coup_prochymal.php . August 4 2015.
59. Tasker F. Stem cell drug saves baby from blood disorder. Miami Herald. 2005 October 14.
60. Cyranoski D. Canada approves stem cell product. Nat Biotech. 2012;30(7):571-.
61. Mack GS. Osiris seals billion-dollar deal with Genzyme for cell therapy. Nat Biotechnol. 2009;27(2):106-7.
62. Bishop T. Osiris shares hold up in IPO:Local stem cell firm is OK treading water. Baltimore Sun. 2006 August 5.
63. Waltz E. Mesoblast acquires Osiris' stem cell business. Nat Biotech. 2013;31(12):1061.
64. Mesoblast - The Regenerative Medicine Company. http://www.mesoblast.com/ . Accessed February 27 2015.
65. Butler D. Translational research: crossing the valley of death. Nature. 2008;453(7197):840-2.
66. Coller BS, Califf RM. Traversing the valley of death: a guide to assessing prospects for translational success. Sci Transl Med. 2009;1(10):10cm9.
67. Meslin EM, Blasimme A, Cambon-Thomsen A. Mapping the translational science policy 'valley of death'. Clin Transl Med. 2013;2(1):14.
68. George J. Regenerative medicine company with local ties files for bankruptcy. Philadelphia Business Journal. 2014 December 30.
69. Somers T. MicroIslet seeks bankruptcy shelter, will continue research. San Diego Union-Tribune. 2008 November 12.
70. George J. Garnet puts forth plan to get out of bankruptcy. Philadelphia Business Journal. 2011 May 13.
71. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med. 2006;355(16):1730-5.
72. Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, Caulfield T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell. 2008;3(6):591-4.
73. Levine AD. Insights from patients' blogs and the need for systematic data on stem cell tourism. Am J Bioeth. 2010;10(5):28-9.
74. Ryan KA, Sanders AN, Wang DD, Levine AD. Tracking the rise of stem cell tourism. Regen Med. 2010;5(1):27-33.
75. Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ. Oversight for clinical uses of autologous adult stem cells: lessons from international regulations. Cell Stem Cell. 2013;13(6):647-51.
76. Sipp D, Turner L. US regulation of stem cells as medical products. Science. 2012;338(6112):1296-7.